Sale!

Dihydrocodeine Continus 60mg

Name: Dihydrocodeine Continus 60mg
SKU: 392
Availability: InStock

£145.00 – £250.00

Dihydrocodeine Continus 60mg is for the relief of severe pain in cancer and other chronic conditions. This tablets are indicated for use in adults and children over 12 years of age.

STRENTH: 60MG

Quantity

Clear

SKU: N/A Category: Pain & Fever Relief

Dihydrocodeine Continus 60mg is for the relief of severe pain in cancer and other chronic conditions.

Dihydrocodeine 60mg tablets are indicated for use in adults and children over 12 years of age.

Posology

Adults and children over 12 years:

One or two tablets 12-hourly.

Elderly:

Dosage should be reduced

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with dihydrocodeine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Paediatric population

Children 12 years or under: Not recommended.

Method of administration

Oral.4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1; severe respiratory depression with hypoxia; severe chronic obstructive lung disease; severe cor pulmonale; severe bronchial asthma; paralytic ileus; acute alcoholism. As dihydrocodeine may cause the release of histamine, it should not be given during an asthma attack.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.4.6 Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data from the use of dihydrocodeine in pregnant women. Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate. Dihydrocodeine should only be used during pregnancy and labour if considered essential due to the risk of neonatal respiratory depression. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available. Infants born to mothers who have received opioids during pregnancy should be monitored for respiratory depression.

Breastfeeding

Administration to nursing women is not recommended as dihydrocodeine may be secreted in breast milk and may cause respiratory depression in the infant. It is advisable that dihydrocodeine only be administered to breast-feeding mothers if considered essential.4.7 Effects on ability to drive and use machines

Dihydrocodeine may cause drowsiness and, if affected, patients should not drive or operate machinery.

This medicine can impair cognitive function and can affect a patient’s ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

▪ The medicine is likely to affect your ability to drive.

▪ Do not drive until you know how the medicine affects you.

▪ It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the ‘statutory defence’).

▪ This defence applies when:

	▪	The medicine has been prescribed to treat a medical or dental problem; and
	▪	You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.